

News Release

Suven Awarded 2005 – Partner of Choice in Drug Discovery for CNS by Frost & Sullivan

Partnered to provide comprehensive drug discovery support services in the drug development programs for Global Life Science companies

HYDERABAD, INDIA (October 3, 2005) – Suven Life Sciences Limited (Suven) today announced that it has been awarded '2005 - Partner of Choice in Drug Discovery for CNS' by Frost and Sullivan at Pharma Alliance 2005 Awards Banquet held in Mumbai on Oct 1, 2005. This award is based on Suven's exhibition of remarkable drug discovery capabilities in the areas of CNS drugs and metabolic disorders in a short span of around 3 years. Suven has produced 10 potential candidates for development of which some are in the near licensing stage.

Suven Life Sciences, a Hyderabad based life sciences company, pioneer in Contract Research And Manufacturing Services (CRAMS) since 1995 in its endeavor to become collaborative research partner for global life science companies has embarked on new business model "Drug Discovery and Development Support Services" (DDDSS) with the onset of Intellectual Property Regime in India since January 2005. Under this business model Suven provides services in the areas of drug discovery research, drug development, late phase clinical development and clinical data management in addition to CRAMS for global pharmaceutical and life science companies.

A focused provider of services in the area of discovery & development and for development of New Chemical Entities for life sciences companies, Suven's commitment to protection of intellectual property, maximization of return on R&D investments for collaborative partners, ability to offer full spectrum of services from discovery to market launch and provide technologies and expertise in different therapeutic areas. Suven has R&D strength of more than 170 professionals with the state of the art infrastructure for advanced drug development activities with the front end project management services from New Jersey , USA . For more information on Suven, please visit our Web site at http://www.suven.com.

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements

that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;